RankingsPricing
  1. US-listed companies
  2. Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc.CTXR

Market cap
$90.67M
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Sep 30,
2011		Sep 30,
2012		Sep 30,
2013		Sep 30,
2015		Sep 30,
2016		Sep 30,
2018		Sep 30,
2019		Sep 30,
2020		Sep 30,
2021		Sep 30,
2022
Net Loss-26,341-22,006-31,369-2,902,268-8,295,698-12,536,638-15,562,144-17,548,085-23,054,434-33,640,646
Stock-based compensation – general and administrative---486,271732,151779,701715,983803,26114
Issuance of common stock for services-------528,77068,000378,204
Amortization of operating lease right-of-use asset---------176,754
Depreciation----1,3431,7538938441,4922,923
Deferred income tax expense---------576,000
Gain from forgiveness of notes payable – paycheck protection program and accrued interest--------166,557-
Prepaid expenses----60,000-40,759-162,514-9,62174,1263111,176
Deposits--------19,031-
Accounts payable906-11,474452,981105,230971,0131-857,307-579,140-111,717
Accrued expenses3,9504,1502,700-52,057351,18270,73964,568-82,185457,920783,434
Accrued compensation-----135,915201,773254,231251,081-143,749
Accrued interest---7,5007,009-15,645-16,443-15,67387,996-
Operating lease liability--------123,254-158,999-177,237
Net Cash Used In Operating Activities-20,781-20,324-20,604-2,385,416-5,900,421-11,318,138-12,437,751-16,930,658-24,250,414-28,361,256
Purchase of property and equipment-------1,8316,938-
Net Cash Used In Investing Activities----255,748---1,831-40,006,938-
Principal paid on notes payable – related parties----600,000---172,970-
Proceeds from sale of NoveCite, Inc. common stock18,00018,00018,000-----82,634-
Net proceeds from private placement---25---18-
Net Cash Provided By Financing Activities36,49356,74077,20925171123120-
Net Change in Cash and Cash Equivalents-------656-28,361,256